Results 161 to 170 of about 61,036 (213)

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. [PDF]

Antimicrob Agents Chemother
Patel M, Nieddu G, DeRyke CA, Young K, Chen LF, Paschke A, Rizk ML, Gheyas F.   +7 more
europepmc   +1 more source

Restoration of Mucosa-Associated Invariant T-Cell Function in Healthcare-Associated Bacterial Infections Supports Recovery of Carbapenem Efficacy Against Resistant Bacteria Ex Vivo. [PDF]

J Infect Dis
Xue Y, Karim AM, Sia WR, Han F, Chan KL, Chua NG, Hadadi L, Liu Z, Mak JYW, Fairlie DP, Wang LF, Sandberg JK, Kwa AL, Leeansyah E.   +13 more
europepmc   +1 more source

Optimisation and validation of capture mNGS for predicting antimicrobial resistance. [PDF]

EBioMedicine
Lin Q, Mei X, Zheng H, Meng J, He F, Yang B, Ru X, Su M, Wang D, Tan N, Fang J, Fu S, Ouyang N, Yang Z, Jiang S, Zhang Y.   +15 more
europepmc   +1 more source

<i>Delftia</i> spp as Opportunistic Pathogens: a narrative review. [PDF]

New Microbes New Infect
Ryan MP, Tony Pembroke J.
europepmc   +1 more source

Spread of carbapenemase-producing <i>Serratia</i> spp. in France from 2016 to 2024: a comparative genomic study. [PDF]

Emerg Microbes Infect
Rezzoug I, Bernabeu S, Ouacel K, Birer A, Jousset AB, Larouy-Maumus G, Bonnin RA, Emeraud C, Dortet L.   +8 more
europepmc   +1 more source

Imipenem-cilastatin and imipenem-relebactam [PDF]

, 2017
The carbapenems are a group of bicyclic beta-lactam compounds with a common carbapenem nucleus. Imipenem (N-formimidoyl-thienamycin: C12H17N3O4S; average molecular weight: 299.3460) is one of these, and it has substantial activity against both aerobic and anaerobic bacteria, including many (but not all) beta-lactamase-producing strains.
Hayashi, Yoshiro, Paterson, David L.
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Imipenem

Mayo Clinic Proceedings, 1991
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. It has the broadest antibacterial activity of all antibiotics available for systemic use in humans. It is active against streptococci, methicillin-sensitive staphylococci, Neisseria, Haemophilus, anaerobes, and the common aerobic gram ...
W C, Hellinger, N S, Brewer
  +5 more sources

Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii [PDF]

Journal of Microbiology, Immunology and Infection, 2014
BackgroundThe optimal combination ratio of imipenem to colistin methanesulfonate (CMS) against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii (INS-MDRAB) has not been determined in previous studies.
Huang Ching Tai, Po-Yen Huang, Jung-Jr Ye   +2 more
exaly   +2 more sources

Imipenem and Aztreonam

Infectious Disease Clinics of North America, 1989
To date, clinical use of aztreonam has been remarkably restrained and widespread enthusiasm for addition to hospital formularies similarly moderate. Its most accepted indication appears to be in gram-negative bacillary infections in the penicillin-allergic individual where one might ordinarily use an extended spectrum penicillin or a third generation ...
openaire   +2 more sources

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin [PDF]

Asian Journal of Pharmaceutical Sciences, 2020
This study aimed to clarify that organic anion transporters (OATs) mediate the drug–drug interaction (DDI) between imipenem and cilastatin. After co-administration with imipenem, the plasma concentrations and the plasma concentration-time curve (AUC) of ...
Kexin Liu, Xiaodong Ma, Changyuan Wang   +2 more
exaly   +2 more sources